Literature DB >> 17267329

New therapeutic approaches for metastatic thyroid carcinoma.

Eric Baudin1, Martin Schlumberger.   

Abstract

Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine and suppressive thyroid hormone treatment. A third of patients with distant metastases (who have radioiodine uptake, are younger than 40 years, have small metastases, and have well differentiated thyroid tumour) can be cured with radioiodine treatment. For other patients, there are no effective treatment modalities. However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267329     DOI: 10.1016/S1470-2045(07)70034-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  58 in total

1.  S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.

Authors:  Martin Nipp; Mareike Elsner; Benjamin Balluff; Stephan Meding; Hakan Sarioglu; Marius Ueffing; Sandra Rauser; Kristian Unger; Heinz Höfler; Axel Walch; Horst Zitzelsberger
Journal:  J Mol Med (Berl)       Date:  2011-09-22       Impact factor: 4.599

2.  Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma.

Authors:  Dong Yeob Shin; Kwang Joon Kim; Cheol Ryong Ku; Mi Kyung Lee; Soo Il Jee; Woong Youn Chung; Eun Jig Lee
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

3.  Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report.

Authors:  Li Jin Duo; Jiang Rong; Wang Bin; Ma Chun Hua; Sun Li Wei; L V Yuan
Journal:  Oncol Lett       Date:  2015-05-04       Impact factor: 2.967

Review 4.  The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?

Authors:  Carmelo Nucera; Jack Lawler; Richard Hodin; Sareh Parangi
Journal:  Oncotarget       Date:  2010-12

Review 5.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

Review 6.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

7.  GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.

Authors:  Jean-Philippe Spano; Y Vano; S Vignot; T De La Motte Rouge; L Hassani; R Mouawad; F Menegaux; D Khayat; L Leenhardt
Journal:  Med Oncol       Date:  2011-09-25       Impact factor: 3.064

8.  Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma.

Authors:  Umut Elboğa; Mesut Özkaya; Zeynel A Sayiner; Yusuf Zeki Çelen
Journal:  BMJ Case Rep       Date:  2016-03-08

9.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

10.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.